SCHEMBL579839

SCHEMBL579839

O=C(Nc1ccc(Oc2ccc(CCNCc3ccccc3)cc2)cc1)c1cccs1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 8/20 0.61
RAB9A P51151 7/20 0.61
OPRM1 P35372 2/20 0.57
OPRD1 P41143 2/20 0.57
OPRK1 P41145 2/20 0.57
TDP1 Q9NUW8 2/20 0.56
LMNA P02545 1/20 0.56
MEN1 O00255 5/20 0.56
KMT2A Q03164 5/20 0.56
KDM4E B2RXH2 2/20 0.56
TP53 P04637 3/20 0.55
ALDH1A1 P00352 1/20 0.55
SMN1; SMN2 Q16637 3/20 0.54
TRPA1 O75762 1/20 0.52
RECQL P46063 1/20 0.51
ATM Q13315 1/20 0.51
CASP3 P42574 1/20 0.50
CASP2 P42575 1/20 0.50
LTA4H P09960 1/20 0.50
EPHX2 P34913 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL579469 0.84 OPRM1 (0.67) NPC1RAB9AOPRM1OPRD1OPRK1
SCHEMBL580457 0.84 OPRM1 (0.58) OPRM1OPRD1OPRK1MEN1KMT2A
SCHEMBL15434968 0.82 LMNA (0.74) NPC1RAB9ATDP1LMNAMEN1
SCHEMBL579511 0.81 OPRM1 (0.61) RAB9AOPRM1OPRD1OPRK1LMNA
SCHEMBL5991688 0.81 RAB9A (0.80) NPC1RAB9ATDP1LMNAMEN1
Thiophene Carboxylic Acid SCHEMBL5738716 0.81 OPRM1 (0.57) NPC1RAB9AOPRM1OPRD1OPRK1
SCHEMBL3264531 0.80 NOS3 (0.64) NPC1RAB9ATDP1LMNAMEN1
SCHEMBL579606 0.80 OPRM1 (0.65) OPRM1OPRD1OPRK1MEN1KMT2A
SCHEMBL580225 0.80 SMN1; SMN2 (0.71) NPC1RAB9AOPRM1OPRD1OPRK1
Hydrochloric Acid SCHEMBL4552003 0.80 NOS3 (0.65) NPC1RAB9ATDP1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1735268-B1 OPIOID RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2012-02-15 EP claimed
EP-1735268-B1 OPIOID RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2012-02-15 EP disclosed
US-20110105571-A1 Opioid Receptor Antagonists ELI LILLY AND COMPANY (US) 2011-05-05 US disclosed
US-7902372-B2 Therapy for obesity; using a secondary amino compound ELI LILLY AND COMPANY (US) 2011-03-08 US disclosed
EP-1735268-A1 OPIOID RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2006-12-27 EP disclosed
WO-2005092836-A1 OPIOID RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2005-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105571-A1 Opioid Receptor Antagonists OPRD1, OPRM1, OPRK1 NPC1 1840/4885RAB9A 1508/4885OPRM1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.